NVAX Novavax Inc

$NVAX 🇯🇵🍣TAKEDA advertisement for Nuvaxovid: To protect yourself and those who matter most to you. Make a thoughtful choice, backed by reliable technology. Ensure peace of mind in your daily life—now and in the future. Nuvaxovid is expected to help prevent infection and the development of severe illness. Side effects following vaccination tend to be relatively mild. Available to individuals aged 12 and older. Prepare for future outbreaks.

$NVAX 2-week candles chart updated. Current 2-week period ends on Friday next week. Added that new Downtrend Line. The bearish signal on 2-week stochastic was triggered and FWIW I'm sharing the backtesting about that signal. GLTA

$NVAX Everything on track and as expected. Only the idiots, liars, disgruntled investors, shorts thought otherwise. We are infested on this board with them. The 3 main banks BofA Citi JPM supporting the Hedge fund clients will capitulate soon. The absurdity of the official analysis is becoming more and more apparent. Look at the revenue estimates going into the 3rd qtr. Even more dramatic is the 4th qtr and 2027. The Nuvaxovid sales are significant added revenue. Add in the milestones , 125m, 75m, 225m none of which are in the current 3 nefarious banks estimates . Thats just Sanofi. Novavax has the proprietary CIC, don’t forget C Diff imo the biggest blockbuster and money maker for Novavax. We talked about Pfizer and Prevnar 35 by year end as well. Merck a high likely next partnership, almost certain. They just all keep it as secret as possible. Jacobs said no problem, silence is our currency. Sanofi EC tomorrow, cic will be discussed. Novavax next week, maybe another catalyst??

$NVAX when this company made the MAJOR partnership with Sanofi, it jumped to $25 / pps. Then they made another MAJOR partnership with Pfizer and the stock jumped again. It seems logical that with 2 MAJOR PLAYERS that Novavax has ALREADY teamed up with, imo, should be at around $40 RIGHT NOW pps. I believe it will in a short time.

$NVAX 1. Cancer Booster (CD8+ T-cells): Official oncological studies (including AACR reports) confirm that Matrix-M induces lysosomal membrane permeabilization and cross-presentation of antigens. This is key in oncology – the adjuvant forces the immune system to generate cytotoxic T-lymphocytes (CD8+), which are the only cells capable of physically destroying tumor masses. 2. Prolonged Immunity (Immunological Memory): While mRNA vaccines provide a rapid but short-lived spike in antibodies, Matrix-M stimulates germinal centers in the lymph nodes, forcing the body to produce long-lived memory B and T cells. As a result, the body's protection lasts significantly longer. 3. Dose Reduction (Antigen Sparing) and Mixing: In official Novavax documentation, this feature is called antigen-sparing. It allows for full immunity using up to a several-fold smaller dose of protein. Big Pharma utilizes this market-wise for heterologous (mix-and-match) vaccinations or combining antigens (as seen in th...

$NVAX with the confirmed $125 million revenue Novavax reached breakeven for 2026. Congratulations!!! First time ever. Real sales and royalties. No accounting papers tricks. Real hard cash money Every extra dollar from covid royalties is pure profit. Fantastic 🏆🏆🏆🏆🏆

$NVAX I still believe something will have to give with Pfizer. It may take two seasons but I don't believe they'll give up their COVID revenue to sanofi and moderna's cic. Their only way out is to partner with novavax on their cic. That's why I predict either sanofi eventually buys out novavax to cut pfizer out or Pfizer cuts a deal.

$NVAX its obvious that Novavax will dramatically increase the forecast for 2026. They got the $125 million plus better understanding of the royalties from Sanofi. We shall see at least 50% upgrade. Share price has to move up. I don’t see other way

$NVAX in the earning call on the 5 Nov Novavax are going to increase the annual 2026 revenue forecast by a massive 50% !!! It was $235-275M. Mid $255M Since they got ontop $125M from Sanofi CIC milestone it will surely be $380M Break even for 2026 On top of that we can expect another income from royalties Nice!!!

$NVAX Prevnar35 makes sense. Look at the adjuvants and the adjuvant free versions has twice the amount of antigen. Matrix M = antigen sparing, type of immune response th1 + th2 etc

$NVAX Maybe this is a nothing burger. But it does seem interesting they would release the PR on the 125 million when they haven’t actually received it yet. That could’ve easily been rolled into the earnings next week. Makes me think that they may have something else that they don’t wanna take attention from next week that might be bigger. That would be sweet.

$NVAX The trap is set, the lines are tight, and the bears are completely out of oxygen. Look at the data. 47.35 MILLION shares are sitting dead short. That is a massive 29.17% of the entire tradeable float trapped at the bottom of the ocean. Days to cover is dragging out between 4.3 to over 8 days depending on the volume window. If they try to crowd through the exit door at once, they will be buying our shares at whatever premium we demand. The fuse is officially lit. Q3 Earnings hit the deck this Thursday, November 5th, before the opening bell. Every single short position is an unexecuted buy order, and they are manifest destiny for a massive squeeze. We aren't locking in gains; we're locking the exit door. Hold the line. 🚀🔥 #ShortSqueeze #Bullish #TopShelfStock

$NVAX goddamn quit with the silence. Make it official already. 35vPnC Indications show that Pfizer intends to use Novavax's Matrix-M saponin-based adjuvant for Prevnar 35. Traditional aluminum phosphate adjuvants struggle to chemically stabilize 35 different conjugate targets simultaneously without structural failure. The Matrix-M platform provides an "open cage" nanoparticle delivery system to handle this complex volume.

$NVAX Pfizer Q3 prints a 10% drop in Prevnar adult market share. Older immune systems require powerful adjuvants—the exact problem Novavax's Matrix-M platform solves. While Pfizer’s 2 licensed fields remain undisclosed, a future development milestone payment disclosure from NVAX would confirm a clinical launch. Fusing this pipeline optionality with a 31.72% short interest and 7.31 Days to Cover makes NVAX highly coiled ahead of Thursday's Q3 earnings. 📊⚓

$NVAX Happy to report Nuvaxovid availability in Ontario 🇨🇦 expanding. Now available in 2 national chains, Rexall and Shoppers Drug Mart. 🇨🇦👍🎃

$NVAX The Nov 5 Inflection: Manifesting the Royalty Shift 🎯 The market is mispricing the structural tape. While retail watches short-term vaccine logistics, institutional algorithms are preparing for a massive transition ahead of Thursday’s opening bell. Nov 5 isn't just an earnings report—it is where $NVAX has the potential to manifest as a high-margin, asset-light biotech royalty engine. 💡 THE METAMORPHOSIS VECTORS: • The Revenue Inflection: Transitioning from volatile sales into locked, global licensing distributions backed by a firm European baseline. • Asymmetric Risk Profile: With the $125M Sanofi milestone de-risking the capital profile, bears face extreme risk against an unshakeable asset floor. • The Multiple Re-Rating: Risk models are processing the shift from a single-product binary play to a high-margin tech infrastructure powerhouse. The speculation cycle is over. The macro math takes over on November 5. #Novavax #Biotech #MacroTrading Bullish

$NVAX what i really learned all over the years with novavax: NEVER expect anything. NEVER!

$NVAX So I want thanks to John Jacobs for not delivering past 4 years. You maybe made the company not to bankrupt, you made the price spike to 24 and yes at that moment i had some not so big but quite significant money and i didnt sell but what is the reality. Reality is that i held the yolo position in nvax 3.5 years already. If the price at least returned at around 20 my life could be significantly better, not fixed but better, i could have at least $75K. But now i hold only partial position, partial in cash and only like 4-5 months remaining in the apartment. I am without income from end of the year (and i can be happy if i get paid yet for last 2 months because income of my employer is collapsing). So i am without money, without job, not possible to get job, and i am leaved with little money. I think that really rough (finish?) is ahead of me in 2027 and further. So thanks again John Jacobs that you didnt make the price spike at least to $20 now 2.5 years already.

$NVAX Next Thurs Nova reports: ++ 2026 Revenue: Reported + PR'd (125M) : ++ Revenue Total for Jacobs' Duration of Stay (2023-26) : $3.1B ++ 2023-26 Loss/Gain: -$228M in Four Yrs. Considering what we've through & Where Platforms are today -- it's just amazing! To build Multiple Platforms will cost BPs Billions ++ 1/2 of Market Cap is CASH : ~$800M ++ Surprising news: Offloading of FLU/CIC to BP for upfront CASH w/ royalty arrangement, to boost Balance Sheet and ultimately resolve the Capital Market issues, namely, Convertible Bonds (225M + 26.6M) ++ Cost Structure: $200M R&D/SG&A for 2027+ & Beyond!

$NVAX 5 years of "Happy Talk" Jacobs. He's gotten fabulously wealthy and shareholders have gotten poor. And he keeps getting rewarded for poor execution and mismanagement.